DelveInsight’s “Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dysmenorrhea Overview
Painful menstrual periods in medical term are described as Dysmenorrhea, which is often called as “menstrual cramps” in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea. Primary dysmenorrhea is common menstrual cramps related to the normal process of menstruation. Whereas, in secondary dysmenorrhea the pain is caused by any disorder in the woman's reproductive organs.
Some of the key facts of the Dysmenorrhea Market Report:
- The Dysmenorrhea market size was valued at USD 7.7 Billion in the year 2019 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In the year 2019, the total prevalent case of Dysmenorrhea was 134,928,831 cases in the 7MM
- The United States, accounted for nearly 43% of the total 7MM cases, in 2019
- Among the EU-5 countries, the highest number of cases of Dysmenorrhea were inGermany, i.e.13,162,395 cases in the year 2019, which is estimated to rise by the year 2032
- AbbVie and Neurocrine Biosciences’s Orilissa (elagolix), is the first and only orally administered, nonpeptide small molecule GnRH antagonist, which is specifically developed for women with moderate to severe endometriosis pain
- Key Dysmenorrhea Companies: Myovant Sciences GmbH, Takeda, Bayer, ObsEva SA, Fuji Pharma’s, Laboratorios Andromaco S.A, Juniper Pharmaceuticals, Inc., and others
- Key Dysmenorrhea Therapies: Relugolix, Yselty, FSN-013, LEP, Meloxicam, Lidocaine, and others
Get a Free sample for the Dysmenorrhea Market Report
Key benefits of the Dysmenorrhea Market report:
- Dysmenorrhea market report covers a descriptive overview and comprehensive insight of the Dysmenorrhea Epidemiology and Dysmenorrhea market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Dysmenorrhea market report provides insights on the current and emerging therapies.
- Dysmenorrhea market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Dysmenorrhea market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Dysmenorrhea market.
Discover more about therapies set to grab major Dysmenorrhea market share @ Dysmenorrhea market forecast
Dysmenorrhea Epidemiology Segmentation:
The Dysmenorrhea market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Dysmenorrhea
- Prevalent Cases of Dysmenorrhea by severity
- Gender-specific Prevalence of Dysmenorrhea
- Diagnosed Cases of Episodic and Chronic Dysmenorrhea
Dysmenorrhea Market
The dynamics of the Dysmenorrhea market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Yselty, FSN-013, and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Dysmenorrhea epidemiology trends @ Dysmenorrhea Epidemiological Insights
Dysmenorrhea Market Drivers
- Increasing prevalence owing to increase in awareness and changing lifestyle
- Emerging Landscape with promising early efficacy signals
Dysmenorrhea Therapies and Key Companies
Relugolix: Myovant Sciences GmbH/ Takeda
- Yselty: ObsEva SA
- FSN-013: Fuji Pharma’s
- LEP: Bayer
- Meloxicam: Laboratorios Andromaco S.A
- Lidocaine: Juniper Pharmaceuticals, Inc.
Scope of the Dysmenorrhea Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Dysmenorrhea Companies: Myovant Sciences GmbH, Takeda, Bayer, ObsEva SA, Fuji Pharma’s, Laboratorios Andromaco S.A, Juniper Pharmaceuticals, Inc., and others
- Key Dysmenorrhea Therapies: Relugolix, Yselty, FSN-013, LEP, Meloxicam, Lidocaine, and others
- Dysmenorrhea Therapeutic Assessment: Dysmenorrhea current marketed and Dysmenorrhea emerging therapies
- Dysmenorrhea Market Dynamics: Dysmenorrhea market drivers and Dysmenorrhea market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Dysmenorrhea Unmet Needs, KOL’s views, Analyst’s views, Dysmenorrhea Market Access and Reimbursement
Dysmenorrhea Market Barriers
- Limitations of the current therapies such as side effects and mediocre efficacy
- The anticipated increasing use of generics
Table of Contents
1. Dysmenorrhea Market Report Introduction
2. Executive Summary for Dysmenorrhea
3. SWOT analysis of Dysmenorrhea
4. Dysmenorrhea Patient Share (%) Overview at a Glance
5. Dysmenorrhea Market Overview at a Glance
6. Dysmenorrhea Disease Background and Overview
7. Dysmenorrhea Epidemiology and Patient Population
8. Country-Specific Patient Population of Dysmenorrhea
9. Dysmenorrhea Current Treatment and Medical Practices
10. Dysmenorrhea Unmet Needs
11. Dysmenorrhea Emerging Therapies
12. Dysmenorrhea Market Outlook
13. Country-Wise Dysmenorrhea Market Analysis (2019–2032)
14. Dysmenorrhea Market Access and Reimbursement of Therapies
15. Dysmenorrhea Market Drivers
16. Dysmenorrhea Market Barriers
17. Dysmenorrhea Appendix
18. Dysmenorrhea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Dysmenorrhea treatment, visit @ Dysmenorrhea Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
